Press Releases

CAHP today issued a statement in response to Gov. Gavin Newsom appointing Dr. Brad Gilbert as the director of the Department of Health Care Services.

California Association of Health Plans President & CEO Charles Bacchi today issued a statement in response to Gov. Gavin Newsom’s release of the 2020-21 state budget proposal.

RunawayRx calls attention to skyrocketing cost of insulin and diabetes treatments during National Diabetes Awareness Month.

September 24, 2019, Sacramento, Calif. – The first major quarterly report providing wholesale drug cost increase information on existing prescription drugs issued by the Office of Statewide Health Planning and Development (OSHPD) was released and made available to the public for the first time yesterday. The report is a result of the passage of Senate Bill 17 (Hernandez) – California’s landmark drug price transparency bill that became law in 2017.

Covered California today announced preliminary health insurance rates for 2020, citing an average weighted statewide rate change of .8 percent, the lowest premium increase since the exchange was established in 2014.

The California State Assembly today passed legislation by a bipartisan vote to contain costs in the dialysis and drug treatment industries that currently result in higher health care costs for all consumers.

The California Association of Health Plans today has released a research review of a recent non-partisan nationwide study conducted by a team of Northwestern University professors which found that allowing managed care organizations (MCO’s) to administer the majority of Medicaid drug benefits, as we currently do in California, significantly reduces state spending on prescription drugs.

AB 824, a bill that would curb increasing drug prices in Californiaby allowing more generic drugs to enter thehealth caremarketplace, cleared the Assembly Health Committee this afternoon. The measure, introduced by Assembly Health Committee Chairman Jim Wood (D-Santa Rosa)inpartnership with Attorney General Xavier Becerra, would prohibit “pay-for-delay” agreements where a pharmaceutical company transfers anything of value to delay a competitor’s research, marketing, or sale of a competing version of its drug.

RunawayRx today released two new infographics. One highlightskey implementation dates for California’s landmark prescription drug transparency law, SB 17, and the other revealsnew details about how prescription drug costs are impacting California health plan premiums.